Resource impact statement
No significant resource impact is anticipated
We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population).
This is because the technology is a further treatment option and is available at a similar price.
The list price of certolizumab pegol has a commercial arrangement (complex patient access scheme) that provides the first 12 weeks of certolizumab pegol free of charge. It is the company’s responsibility to let relevant NHS organisations know details of the arrangement.
A resource impact template is provided for completion at a local level. This is because there are now several treatment options (biological and non-biological therapies) that are recommended by NICE for plaque psoriasis which can be branded or be a biosimilar.
Therefore, organisations should complete both current and future uptake based on local practice.
This technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts.
This page was last updated: